---
figid: PMC5940413__oncotarget-09-21444-g005
figtitle: Functional significance of co-occurring mutations in PIK3CA and MAP3K1 in
  breast cancer
organisms:
- Escherichia coli
- Armoracia rusticana
- Lareunionomyces loeiensis
- Streptococcus pyogenes
- Homo sapiens
- Mus musculus
- Bos taurus
organisms_ner:
- Homo sapiens
- Mus musculus
- Bos taurus
- Drosophila melanogaster
pmcid: PMC5940413
filename: oncotarget-09-21444-g005.jpg
figlink: /pmc/articles/PMC5940413/figure/F5/
number: F5
caption: Illustration contemplating experimental (in vitro, 3D organoids and in vivo)
  and clinical observations presented in the study. AZD5363 can be used as an efficient
  compound to treat mPIK3CA tumors by blocking the pathway at the level of AKT. However
  its efficiency may be compromised in patients harboring co-occurring MAP3K1 LoF
  mutation. Patients with reduced MAP3K1 expression have deregulated JNK pathway activity
  and consequently decreased phospho-serine IRS1 (S312) levels. This increases IRS1
  stability and subsequently brings about the re-activation of PI3Kα. pS, phospho-serine,
  GF, growth factor, GF-R, growth factor receptor.
papertitle: Functional significance of co-occurring mutations in PIK3CA and MAP3K1
  in breast cancer.
reftext: Alvaro Avivar-Valderas, et al. Oncotarget. 2018 Apr 20;9(30):21444-21458.
year: '2018'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9215798
figid_alias: PMC5940413__F5
figtype: Figure
redirect_from: /figures/PMC5940413__F5
ndex: 72672577-df0e-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5940413__oncotarget-09-21444-g005.html
  '@type': Dataset
  description: Illustration contemplating experimental (in vitro, 3D organoids and
    in vivo) and clinical observations presented in the study. AZD5363 can be used
    as an efficient compound to treat mPIK3CA tumors by blocking the pathway at the
    level of AKT. However its efficiency may be compromised in patients harboring
    co-occurring MAP3K1 LoF mutation. Patients with reduced MAP3K1 expression have
    deregulated JNK pathway activity and consequently decreased phospho-serine IRS1
    (S312) levels. This increases IRS1 stability and subsequently brings about the
    re-activation of PI3Kα. pS, phospho-serine, GF, growth factor, GF-R, growth factor
    receptor.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PIK3CA
  - MAP3K1
  - RAPGEF5
  - IRS1
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - GRB2
  - MAPK8
  - MAPK9
  - MAPK10
  - AKT1
  - AKT2
  - AKT3
  - XYLT2
  - SOS1
  - SOS2
  - MTOR
  - MAPK3
  - MAPK1
  - ANXA6
  - UBASH3B
  - Pik3ca
  - Map3k1
  - Rapgef5
  - Irs1
  - Pik3r1
  - Grb2
  - Mapk8
  - Akt1
  - Mtor
  - Mapk3
  - Mapk1
  - Elf1
  - Il2rb
  - Ubash3b
  - .na.character
  - gfr
  - nac
  - es
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - drk
  - bsk
  - Akt
  - Sos
  - Tor
  - rl
  - WDR79
  - tral
  - rump
  - MED17
  - SF1
  - Irbp
  - Low
  - AZD5363
---
